Comparison of Short Acting versus Long Acting Filgrastim for Reduction of Chemotherapy Induced Febrile Neutropenia

Introduction: Febrile neutropenia (FN) is the most frequent complications reported during cytotoxic chemotherapy treatment. Granulocyte colony stimulating factor (GCSF) used to reduce and related complications. This study compares short versus long acting filgrastim for reduction of induced FN. Methods: Histologically confirmed solid cancer patients (n=112) receiving either high risk or intermediate regimens FN were randomized into two groups. Group one received 300 mcg subcutaneously five days group pegfilgrastim 6 mg single dose, starting after 24 hours completion each cycle. The primary end point was occurrence secondary points number hospital visits, duration stay total direct costs pegfilgrastim. Results: Fifty six analyzed in group. incidence significantly lower (42.90%) than (69.6%), p<0.004. mean visits 1.84±1.93 0.84±1.19 with 58.90% 33.90% admission respectively both 4.14±3.69 2.36±3.35 cost (Nepali rupees) 20162.50+6645.37 (US$168.17±55.42) 32210.71±10429.43($268.67±86.99) respectively. Conclusion: Single dose better multiple doses reducing chemotherapy.